A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

A Multicenter, Non-randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.

Study Overview

• Status: Recruiting
• Conditions: Advanced or Metastatic Breast Cancer
• Intervention / Treatment: Drug: MRG002

Detailed Description

The study will be conducted in two parts. The first part is efficacy exploration and the second part is efficacy verification. During the course of efficacy exploration, 33 subjects will be enrolled to preliminarily evaluate the safety and efficacy of MRG002. The second part will be adjusted according to the result of the first part. 29 subjects are planned to be enrolled. Considering the dropout rate of 10%, approximately 33 subjects are planned to be enrolled. A total of 66 subjects are planned to be enrolled in efficacy exploration and verification.

• Study Type: Interventional
• Enrollment (Anticipated): 66
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100071
      • Recruiting
      • Fifth Medical Center of PLA General Hospital
      • Contact: Zefei Jiang, Doctor; Phone Number: 86-010-66947797; Email: jiangzefei@csco.org.cn
  • Hebei
    • Shijiazhuang, Hebei, China, 050035
      • Recruiting
      • The Fourth Hospital of Hebei Medical University
      • Contact: Cuizhi Geng, Doctor; Phone Number: 86-0311-66696311; Email: gengcuizhi@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntary to sign the ICF and follow the requirements specified in the protocol;
2. Aged ≥ 18, both genders;
3. Expected survival time ≥ 12 weeks;
4. The score of ECOG for performance status is 0 or 1;
5. Subjects with histologically confirmed HER2-low breast cancer, are currently in the locally advanced or metastatic stage, and are ineligible for radical excision, and have received at least first-line standard treatment for recurrent or metastatic breast cancer;
6. Archival or biopsy tumor specimens should be provided;
7. Subjects must have imaging evidence of tumor progression during or after the most recent treatment confirmed by the investigator and at least one measurable lesion at the baseline according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1);
8. Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade 1 (except for alopecia, non-clinically significant or asymptomatic laboratory abnormalities);
9. No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%;
10. The level of organ functions must meet the basic requirements;
11. Reproductive male subjects and female subjects of childbearing age shall be willing to take effective contraceptive measures from the date signing the ICF to 6 months after the last dose of the IP.

Exclusion Criteria:

1. With previous history of other primary malignancies;
2. Received chemotherapy, radiotherapy, biotherapy, immunotherapy, or other anti-tumor drugs within 4 weeks prior to the first dose;
3. The subjects have central nervous system (CNS) metastasis;
4. Subjects with clinical symptoms of pleural effusion, seroperitoneum or pericardial effusion, for which treatment by puncture and drainage is required;
5. Subjects with peripheral neuropathy of greater than Grade 2 (NCI CTCAE v5.0);
6. Any severe or uncontrolled systemic disease;
7. Patients with poorly controlled heart disease;
8. Evidence of active infection, including but not limited to hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection, uncontrolled active bacterial infection, infection caused by other viruses, fungi, rickettsia or parasites;
9. History of hypersensitivity to any component of MRG002 or history of hypersensitivity of ≥ Grade 3 to trastuzumab injection;
10. Disease progression or recurrence occurred during or after the previous treatment, without evidence of CT/MRI examination results;
11. Subjects with uncontrolled concurrent diseases may have limited ability to obey the study requirements or impaired ability to sign the written ICF;
12. Subjects with active autoimmune disease or a history of autoimmune disease are receiving immunosuppressive agents or systemic hormone therapy, and are still receiving within 2 weeks prior to enrollment;
13. Received anti-tumor vaccine treatment 4 weeks prior to the first dose, or plan to participate in anti-tumor vaccine studies;
14. History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc;
15. Pulmonary embolism or deep vein thrombosis occurred within 3 months prior to the first dose;
16. Female subjects with positive result in serum pregnancy test, or female subjects within lactation period and do not agree to take adequate contraceptive measures during the trial and 6 months after receiving the IP;
17. Other conditions inappropriate for participation in this study, as deemed by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MRG002; MRG002 will be administrated via intravenous infusion of 2.6 mg/kg once on Day 1 of every 3 weeks (21-day cycle).	Drug: MRG002; Administrated intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) by Independent Review Committee(IRC)	ORR was defined as the proportions of subjects with a complete response (CR) and partial response (PR). ORR will be assessed by Independent Review Committee (IRC) according to RECIST v1.1.	Baseline to study completion (12 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) by Investigator	ORR was defined as the proportions of subjects with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.	Baseline to study completion (12 months)
Progression Free Survival (PFS)	PFS was defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.	Baseline to study completion (12 months)
6-month and 12-month Progression Free Survival Rate (PFSR)	The proportions of subjects surviving without progression from the start of treatment to 6-month and 12-month duration.	Baseline to study completion (12 months)
Time to Response (TTR)	TTR was defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation.	Baseline to study completion (12 months)
Duration of Response (DoR)	DOR was defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.	Baseline to study completion (12 months)
Disease Control Rate (DCR)	DCR was defined as the proportions of subjects achieving CR, PR, and stable disease (SD) after treatment.	Baseline to study completion (12 months)
Overall Survival (OS)	OS was defined as the duration from the start of treatment to death of any cause.	Baseline to study completion (12 months)
Incidence of Adverse Events (AEs)	Incidence of AEs and serious adverse events (SAEs) will be assessed based on NCI-CTCAE v5.0.	Baseline to 30 days after the last dose of study treatment
Pharmacokinetics (PK) parameter for MRG002: concentration-time curve	Concentration-time curve will be depicted based on pharmacokinetics concentration set (PKCS).	Baseline to 14 days after decision to discontinue treatment
Immunogenicity	The incidence of anti-drug antibody (ADA) analysis will be summarized for all patients who received at least one cycle study treatment.	Baseline to 14 days after decision to discontinue treatment

Collaborators and Investigators

• Sponsor: Shanghai Miracogen Inc.
• Investigators: Principal Investigator: Zefei Jiang, Doctor, Fifth Medical Center of PLA General Hospital; Principal Investigator: Cuizhi Geng, Doctor, The Fourth Hospital of Hebei Medical University

Study record dates

Study Major Dates

• Study Start (Actual): May 13, 2021
• Primary Completion (Anticipated): February 1, 2023
• Study Completion (Anticipated): February 1, 2023

Study Registration Dates

• First Submitted: February 4, 2021
• First Submitted That Met QC Criteria: February 4, 2021
• First Posted (Actual): February 5, 2021

Study Record Updates

• Last Update Posted (Actual): September 7, 2022
• Last Update Submitted That Met QC Criteria: September 6, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: HER2; MRG002; Antibody Drug Conjugate (ADC); Breast Cancer (BC)
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: MRG002-005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No